Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving -3.13% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.28%. On ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

These aren't for the faint of heart.

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive ...